Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
Portfolio Pulse from
Akebia Therapeutics (AKBA) reported a Q4 loss of $0.10 per share, which was larger than the Zacks Consensus Estimate of a $0.08 loss. However, the company exceeded revenue expectations.
March 13, 2025 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Akebia Therapeutics reported a Q4 loss of $0.10 per share, missing the Zacks Consensus Estimate of a $0.08 loss. Despite this, the company exceeded revenue expectations.
The larger-than-expected loss per share is likely to negatively impact investor sentiment in the short term, despite the positive revenue performance. The market often reacts more strongly to earnings per share misses.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100